Pages that link to "Q63440155"

The following pages link to Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation (Q63440155):

Displaying 36 items.

• Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review (Q26770716) (← links)
• The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma (Q26822480) (← links)
• Customized targeted therapy in Hodgkin lymphoma: hype or hope? (Q27002554) (← links)
• Pembrolizumab in classical Hodgkin's lymphoma (Q28079273) (← links)
• Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab (Q33704061) (← links)
• NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr (Q34044024) (← links)
• The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future (Q35038852) (← links)
• Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma (Q35754532) (← links)
• Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation (Q36092021) (← links)
• Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome (Q37082736) (← links)
• Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (C (Q37254243) (← links)
• Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis (Q37388718) (← links)
• Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? (Q37585103) (← links)
• Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors (Q37716119) (← links)
• Allogeneic Hematopoietic Stem Cell Transplantation: Does It Have a Place in Treating Hodgkin Lymphoma? (Q37781731) (← links)
• Optimal treatment for relapsing patients with Hodgkin lymphoma (Q37810094) (← links)
• Hematopoietic Cell Transplantation for Lymphomas (Q37942817) (← links)
• Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies (Q38098957) (← links)
• Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! (Q38179975) (← links)
• The role of allogeneic stem cell transplantation in Hodgkin's lymphoma (Q38206138) (← links)
• Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab (Q38687582) (← links)
• Hematopoietic stem cell transplantation for Hodgkin's disease (Q41902211) (← links)
• Alemtuzumab in allogeneic hematopoetic stem cell transplantation (Q42149544) (← links)
• Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. (Q42795536) (← links)
• High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors (Q44780860) (← links)
• Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. (Q45936276) (← links)
• Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder (Q46734531) (← links)
• Hodgkin lymphoma: A review and update on recent progress (Q47807176) (← links)
• Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. (Q52721221) (← links)
• Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation. (Q53057392) (← links)
• Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. (Q53315058) (← links)
• Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. (Q54686087) (← links)
• Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group (Q84906177) (← links)
• Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula (Q85084463) (← links)
• Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? (Q88321701) (← links)
• Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies (Q89940657) (← links)